Abstract 128P
Background
Biliary tract cancers are heterogeneous tumors defined by the anatomical location, intrahepatic, cholangiocarcinoma (ICC), extrahepatic (ECC), gallbladder and ampulla of Vater cancer (AVC).The outcome of treatment by location remains unclear in Latin American population, resulting in inconsistently data to enhance treatment decisions and outcome. The aim of this study is to describe the epidemiological features and prognosis of overall survival of Latin American population with biliary tract cancers.
Methods
Retrospective, observational study. Included patients treated at the National Cancer Institute between 2008 and 2022. Statistical analysis required: X2 and t test, Kaplan Meier, Log Rank and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.
Results
A total 786 of patients diagnosed with biliary tract cancer were included in the analysis. Patients had a median age of 61 years (24-96). Alcohol consumption and smoking were observed in 22% and 29% respectively. Regarding comorbidities, 22% had Type2DM, 27% HAS, and obesity & overweight was present in 13% and 32% respectively. Anatomical location included ICC (19%;n=151), ECC (22%;n=172), gallbladder (33%;n=259) and AVC (26%;n=204). Female were more prevalent in gallbladder and ICC (79% & 71%) (p<0.001). Median time to diagnosis was 3 months (0–120); extent of disease was observed as localized (18%;n=144), local-advanced (20%;n=158), and metastatic (60%;n=472). In metastatic patients, mean number of metastasis was 1 (1-7), being liver (66%), retroperitoneum (7%), and lung (6%) the most frequent sites. Comparing Chemotherapy and extent of disesase, 35%, 53%, and 55% patients received treatment for localized, unresectable, and metastatic (p=0.001). An OS analysis was conducted considering location, ICC patients showed a median-OS of 9months, ECC a median-OS of 12months, gallbladder a median-OS of 1months and AVC did not reach median-OS (p<0.001).
Conclusions
Prognosis and outcome for patients with biliary tract cancer differ depending on the anatomical subsite. This is one of the main studies describing epidemiological features, and outcome in Latin American patients with biliary tract.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17